A New Tool to Delay Type 1 Diabetes: What Teplizumab Means for Families

For years, doctors diagnosed Type 1 diabetes only after symptoms appeared—when the pancreas could no longer make enough insulin. But research has revealed that the disease develops in stages, long before a person feels sick. Type 1 diabetes now has defined stages: Stage 1 involves autoimmunity with no symptoms, Stage 2 adds early blood sugar changes, and Stage 3 is when insulin deficiency causes clinical symptoms.

This shift in understanding has opened a crucial opportunity. Rather than waiting for diabetes to fully develop, doctors can now identify people at risk and potentially slow or delay the disease's progression using targeted treatments. This approach is called precision medicine—treating disease before it becomes a crisis.

The key to early intervention is early detection. Screening programs now use blood tests to look for autoantibodies—markers of the immune system attacking the pancreas—in children and adults who may be at risk. Identifying people in the early stages of the disease, before they develop clinical symptoms, creates an opportunity to introduce disease-modifying treatments.

Public health screening programs using autoantibody testing are expanding. This approach has an added benefit: by catching Type 1 diabetes earlier, screening can reduce the number of people who experience diabetic ketoacidosis (a serious and potentially life-threatening complication) at diagnosis.

In November 2022, teplizumab became the first medication approved by the U.S. Food and Drug Administration to delay the onset of Type 1 diabetes. It is an immunotherapy—a drug that modifies how the immune system behaves. Teplizumab was approved for people ages 8 and older who have been diagnosed with Stage 2 Type 1 diabetes.

Clinical trials showed that teplizumab helped preserve the pancreas's ability to produce insulin. In a combined analysis of five trials involving 609 patients, people receiving teplizumab had measurable improvements in C-peptide (a marker of the body's own insulin production) at one and two years after treatment. The drug also reduced the amount of insulin patients needed to inject by an average of 0.08 to 0.10 units per kilogram of body weight per day.

It's important to understand what teplizumab does and does not do. The drug delays the onset of clinical Type 1 diabetes—meaning it buys time before a person needs insulin therapy. It is not a cure, and it does not reverse the autoimmune process completely.

Like all medications, teplizumab has side effects. In clinical trials involving over 1,000 patients, the most common adverse events included lymphopenia (low white blood cells), rash, and headache. The majority of these side effects occurred during the first few weeks of treatment and resolved without intervention.

Overall, teplizumab's safety profile in these trials was consistent across multiple studies. However, any medication carries risks, and individual experiences may vary. Families considering teplizumab should discuss potential benefits and risks with their diabetes care team.

Teplizumab is part of a larger transformation in Type 1 diabetes treatment. Researchers are also developing other immune-based therapies to preserve beta-cell function, exploring stem cell-derived approaches to replace damaged insulin-producing cells, and improving insulin delivery through automated systems and new insulin formulations.

While these innovations offer genuine hope, scaling them to reach all families who could benefit remains a challenge. Early screening, disease staging, and treatments like teplizumab represent real progress—but access, affordability, and awareness will determine how widely these advances reach the Type 1 diabetes community.

Origin: YouTube (Video report). Evidence: Video report, corroborated with 4 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.